clinical trial · NCT07221253
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Biliary Tract CancerRilvegostomigDurvalumabGemcitabine/Cisplatin
brief summary
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
started
Dec 4, 2025
primary completion
Jul 31, 2029
completion
Jul 31, 2029
last updated
Jun 18, 2026
official title
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol